Compare FOFO & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | HBIO |
|---|---|---|
| Founded | 2017 | 1901 |
| Country | Hong Kong | United States |
| Employees | 14 | 339 |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 24.9M |
| IPO Year | N/A | 2000 |
| Metric | FOFO | HBIO |
|---|---|---|
| Price | $2.37 | $5.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 60.1K | 36.7K |
| Earning Date | 03-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $0.28 |
| 52 Week High | $68.00 | $7.50 |
| Indicator | FOFO | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 42.60 |
| Support Level | $2.34 | $4.42 |
| Resistance Level | $5.74 | $5.79 |
| Average True Range (ATR) | 0.31 | 0.45 |
| MACD | -0.01 | -0.27 |
| Stochastic Oscillator | 6.73 | 1.33 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.